InflaRx N.V.
We are preparing, please wait
Undervalued or Overvalued?
Unfortunately, this content is only accessible to registered users
Login to ContinueKey stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Market Cap
$94.80 M
Change
$0.08
EPS
-$0.76
P/E Growth
-2.12
Winzerlaer Str. 2, Jena, 07745
Sector:
Industry:
Fiscal Year-end
December
Revenue
$63,089
Net Income
$-42,667,529
2023 Sales Growth
0.00%
InflaRx N.V.'s CEO, Dr. Niels C. Riedemann M.D., Ph.D.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Price
P/E CURRENT
$2.39
Changes Percentage
P/E CURRENT
3.46%
Change
P/E CURRENT
$0.08
Year High
P/E CURRENT
$2.82
An income statement known as a profit and loss statement, is a financial report that summarizes a company's revenues, expenses, gains, and losses over a specific period. It provides insight into a company's operational efficiency and profitability, helping investors and stakeholders assess financial performance and make informed decisions.
The Financials Balance Sheet report provides a clear and concise visual summary of a company’s financial standing through interactive charts. This section highlights key components such as assets, liabilities, and equity, offering investors an at-a-glance understanding of the company's financial health. By showcasing these critical metrics in an easy-to-digest format, the report enables stakeholders to evaluate the company’s stability, operational efficiency, and capital structure, fostering more informed investment decisions.
The Financials Cash Flow report uses charts to provide a clear breakdown of a company’s cash flow across operating, investing, and financing activities. This visualization helps investors quickly assess how the company generates, spends, and manages cash, offering valuable insights into its liquidity and financial efficiency.
Market Benchmark Score
Market Score: Aggregate the average P/E ratio of all companies in the market.
Industry Score: Aggregate the average P/E ratio of all companies in the same industry.
ASSETS
$120.21 M
LIABILITIES
$17.63 M
DEBT Equity Ratio
0.00
Operating Cash Flow
$-37,812,966
The latest Technical Analysis Summary on Stocks.News offers insights into market trends using key Technical Indicators like RSI and MACD, alongside Moving Averages such as the 50-day and 200-day. The analysis identifies buy and sell signals through bullish or bearish crossovers, helping investors make informed trading decisions.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Today's price of InflaRx N.V. is $2.39 — it has increased by +3.46%
Yes, you can track InflaRx N.V.'s financials in yearly and quarterly reports directly on Stocks.News.
Watch the InflaRx N.V. chart and read a more detailed InflaRx N.V. stock forecast to see what analysts suggest you do with its shares.
The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by InflaRx N.V. stock ticker.
Like other stocks, IFRX shares are sold on stock exchanges such as NASDAQ The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.
InflaRx N.V. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in InflaRx N.V.’s financial statements.
